Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. Its lead program, PLN-101095, is an oral small-molecule dual-selective inhibitor of αvβ8 and αvβ1 integrins being developed for solid tumors, including immune checkpoint inhibitor-refractory advanced or metastatic disease.
Company updates commonly cover Phase 1 and Phase 1b oncology data, scientific-conference presentations, combination studies with pembrolizumab, financial results, and healthcare investor-conference participation. Pliant also describes preclinical platform work using integrin receptor-binding molecules for tissue-specific delivery and internalization of drug payloads, including programs directed to skeletal muscle cells, adipocytes, and renal cells.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology firm, announced participation in the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 3:45 p.m. ET. Bernard Coulie, M.D., Ph.D., President and CEO, and Éric Lefebvre, M.D., Chief Medical Officer, will engage in a fireside chat accessible via their Investor Relations page. Pliant's lead product, bexotegrast, is focused on treating idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) and has received Fast Track and Orphan Drug Designations. They are also advancing programs for nonalcoholic steatohepatitis (NASH) and solid tumors, with ongoing Phase 2a trials.
Pliant Therapeutics (PLRX) announced it will present three scientific posters at the 2023 American Thoracic Society (ATS) International Conference from May 19-24, 2023, in Washington, DC. Highlights include data from the Phase 2a trial of bexotegrast (PLN-74809), a dual-selective integrin inhibitor being developed for idiopathic pulmonary fibrosis (IPF). Two of the presentations have been selected for featured oral presentations. The company emphasizes the drug's mechanism of action and its ongoing clinical development, which has received FDA Fast Track and Orphan Drug Designations.